Interleukin-12 family cytokines and sarcoidosis

Frontiers in Pharmacology

Volumn 5, Issue OCT, 2014, Pages

  Ringkowski, Sabine ^a,b,c   Thomas, Paul S ^a,b   Herbert, Cristan ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b PRINCE OF WALES HOSPITAL   (Australia)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Anergy; Granuloma; Il 12; Il 23; Il 27; Il 35; Pathogenesis; Sarcoidosis

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; BACTERIAL ANTIGEN; FONTOLIZUMAB; FUNGUS ANTIGEN; GAMMA INTERFERON; HLA DRB1 ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 12 RECEPTOR BETA1; INTERLEUKIN 12 RECEPTOR BETA2; INTERLEUKIN 12P35; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 17; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 23 RECEPTOR; INTERLEUKIN 23P19; INTERLEUKIN 27; INTERLEUKIN 35; STAT3 PROTEIN; USTEKINUMAB;

CLONAL ANERGY; CROHN DISEASE; CYTOKINE PRODUCTION; FIBROSIS; GENETIC POLYMORPHISM; GRANULOMA; HUMAN; INCIDENCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATHOGENESIS; PREVALENCE; PROPIONIBACTERIUM ACNES; REGULATORY T LYMPHOCYTE; REMISSION; SARCOIDOSIS; SHORT SURVEY; TH1 CELL; TH17 CELL;

EID: 84908329734     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2014.00233     Document Type: Short Survey

References (150)

1. Boeck C. Multipelt benignt hud-sarkoid: Steen'ske bogtrykkeri (1899).
2. Müller-Quernheim J, Prasse A, Zissel G. Pathogenesis of sarcoidosis. La Presse Médicale (2012) 41(6):275-87.
3. Heinle R, Chang C. Diagnostic Criteria for Sarcoidosis. Autoimmunity Reviews (2014).
4. Adrianto I, Lin CP, Hale JJ, Levin AM, Datta I, Parker R, et al. Genome-wide association study of African and European Americans implicates multiple shared and ethnic specific loci in sarcoidosis susceptibility. PLoS One (2012) 7(8):e43907.
5. Dubaniewicz A, Holownia A, Kalinowski L, Wybieralska M, Dobrucki IT, Singh M. Is mycobacterial heat shock protein 16kDa, a marker of the dormant stage of Mycobacterium tuberculosis, a sarcoid antigen? Human Immunology (2013) 74(1):45-51.
6. Negi M, Takemura T, Guzman J, Uchida K, Furukawa A, Suzuki Y, et al. Localization of Propionibacterium acnes in granulomas supports a possible etiologic link between sarcoidosis and the bacterium. Modern Pathology (2012) 25(9):1284-97.
7. Broos CE, van Nimwegen M, Hoogsteden HC, Hendriks RW, Kool M, van den Blink B. Granuloma formation in pulmonary sarcoidosis. Frontiers in Immunology (2013) 4.
8. Iannuzzi MC, Fontana JR. Sarcoidosis: clinical presentation, immunopathogenesis, and therapeutics. Journal of the American Medical Association (2011) 305(4):391-9.
9. Loke WSJ, Herbert C, Thomas PS. Sarcoidosis: Immunopathogenesis and Immunological Markers. International Journal of Chronic Diseases (2013) 2013.
10. Lee N-S, Barber L, Kanchwala A, Childs CJ, Kataria YP, Judson MA, et al. Low levels of NF-κB/p65 mark anergic CD4+ T cells and correlate with disease severity in sarcoidosis. Clinical and Vaccine Immunology (2011) 18(2):223-34.
11. Mroz RM, Korniluk M, Stasiak-Barmuta A, Chyczewska E. Increased levels of interleukin-12 and interleukin-18 in bronchoalveolar lavage fluid of patients with pulmonary sarcoidosis. Journal of Physiology and Pharmacology: An Official Journal of the Polish Physiological Society (2008) 59 Suppl 6:507-13.
12. Judson MA, Marchell RM, Mascelli M, Piantone A, Barnathan ES, Petty KJ, et al. Molecular profiling and gene expression analysis in cutaneous sarcoidosis: the role of interleukin-12, interleukin-23, and the T-helper 17 pathway. Journal of the American Academy of Dermatology (2012) 66(6):901-10. doi: 10.1016/j.jaad.2011.06.017.
13. Larousserie F, Pflanz S, Coulomb-L'Herminé A, Brousse N, Kastelein R, Devergne O. Expression of IL-27 in human Th1-associated granulomatous diseases. The Journal of Pathology (2004) 202(2):164-71.
14. Rybicki BA, Iannuzzi MC, Epidemiology of sarcoidosis: recent advances and future prospects. Seminars in Respiratory and Critical Care Medicine, 2007: New York: Thieme Medical Publishers. editors.
15. Nicholson T, Plant B, Henry M, Bredin C. Sarcoidosis in Ireland: regional differences in prevalence and mortality from 1996-2005. Sarcoidosis (2010).
16. Deubelbeiss U, Gemperli A, Schindler C, Baty F, Brutsche MH. Prevalence of sarcoidosis in Switzerland is associated with environmental factors. European Respiratory Journal (2010) 35(5):1088-97.
17. Erdal BS, Clymer BD, Yildiz VO, Julian MW, Crouser ED. Unexpectedly high prevalence of sarcoidosis in a representative US Metropolitan population. Respiratory Medicine (2012) 106(6):893-9.
18. Eishi Y. Etiologic link between sarcoidosis and Propionibacterium acnes. Respiratory Investigation (2013) 51(2):56-68.
19. Newman LS, Rose CS, Bresnitz EA, Rossman MD, Barnard J, Frederick M, et al. A case control etiologic study of sarcoidosis: environmental and occupational risk factors. American Journal of Respiratory and Critical Care Medicine (2004) 170(12):1324-30.
20. Rybicki BA, Iannuzzi MC, Frederick MM, Thompson BW, Rossman MD, Bresnitz EA, et al. Familial aggregation of sarcoidosis: A case-control etiologic study of sarcoidosis (ACCESS). American Journal of Respiratory and Critical Care Medicine (2001) 164(11):2085-91.
21. Iwai K, Takahashi S. Transmissibility of sarcoid-specific granulomas in the footpads of mice. Annals of the New York Academy of Sciences (1976) 278:249-59.
22. Mitchell DN, Rees RJ, Goswami KK. Transmissible agents from human sarcoid and Crohn's disease tissues. Lancet (1976) 2(7989):761-5.
23. Ikonomopoulos J, Gazouli M, Dontas I, Sechi L, Lukas JC, Balaskas C, et al. The infectivity of sarcoid clinical material and its bacterial content inoculated in CBA mice. In Vivo (2006) 20(6B):807-13.
24. Ikonomopoulos JA, Gorgoulis VG, Kastrinakis NG, Galanos AA, Karameris A, Kittas C. Experimental inoculation of laboratory animals with samples collected from sarcoidal patients and molecular diagnostic evaluation of the results. In Vivo (2000) 14(6):761-5.
25. Burke WM, Keogh A, Maloney PJ, Delprado W, Bryant DH, Spratt P. Transmission of sarcoidosis via cardiac transplantation. Lancet (1990) 336(8730):1579. doi: 10.1016/0140-6736(90)93354-R.
26. Heyll A, Meckenstock G, Aul C, Sohngen D, Borchard F, Hadding U, et al. Possible transmission of sarcoidosis via allogeneic bone marrow transplantation. Bone Marrow Transplantation (1994) 14(1):161-4.
27. Das BB, Shoemaker L, Kim E, Mascio CE, Austin EH. Severe calcification of the aorta (porcelain aorta) associated with sarcoidosis in a pediatric heart transplant recipient. Pediatric Transplantation (2012) 16(5):E162-6. doi: 10.1111/j.1399-3046.2011.01557.x.
28. Padilla ML, Schilero GJ, Teirstein AS. Donor-acquired sarcoidosis. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases: Official Journal of WASOG / World Association of Sarcoido (2002) 19(1):18-24.
29. Pukiat S, McCarthy PL, Jr., Hahn T, Morrison C, Shanahan T, Qiu J, et al. Sarcoidosis-associated MHC Ags and the development of cutaneous and nodal granulomas following allogeneic hematopoietic cell transplant. Bone Marrow Transplantation (2011) 46(7):1032-4. doi: 10.1038/bmt.2010.235.
30. Drake WP, Oswald-Richter K, Richmond BW, Isom J, Burke VE, Algood H, et al. Oral antimycobacterial therapy in chronic cutaneous sarcoidosis: a randomized, single-masked, placebo controlled study. Journal of the American Academy of Dermatology (2013) 149(9):1040-9.
31. Takemori N, Nakamura M, Kojima M, Eishi Y. Successful treatment in a case of Propionibacterium acnes-associated sarcoidosis with clarithromycin administration: a case report. Journal of medical case reports (2014) 8(1):15. doi: 10.1186/1752-1947-8-15.
32. Tercelj M, Rott T, Rylander R. Antifungal treatment in sarcoidosis--a pilot intervention trial. Respiratory Medicine (2007) 101(4):774-8. doi: 10.1016/j.rmed.2006.08.005.
33. Terčelj M, Salobir B, Zupancic M, Rylander R. Antifungal medication is efficient in the treatment of sarcoidosis. Therapeutic Advances in Respiratory Disease (2011) 5(3):157-62.
34. Milman N, Lisby G, Friis S, Kemp L. Prolonged culture for mycobacteria in mediastinal lymph nodes from patients with pulmonary sarcoidosis. A negative study. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases: Official Journal of WASOG / World Association of Sarcoido (2004) 21(1):25-8.
35. Oswald-Richter KA, Beachboard DC, Seeley EH, Abraham S, Shepherd BE, Jenkins CA, et al. Dual analysis for mycobacteria and propionibacteria in sarcoidosis BAL. Journal of Clinical Immunology (2012) 32(5):1129-40. doi: 10.1007/s10875-012-9700-5.
36. Gupta D, Agarwal R, Aggarwal AN, Jindal SK. Molecular evidence for the role of mycobacteria in sarcoidosis: a meta-analysis. The European Respiratory Journal (2007) 30(3):508-16. doi: 10.1183/09031936.00002607.
37. Oswald-Richter KA, Culver DA, Hawkins C, Hajizadeh R, Abraham S, Shepherd BE, et al. Cellular responses to mycobacterial antigens are present in bronchoalveolar lavage fluid used in the diagnosis of sarcoidosis. Infection and Immunity (2009) 77(9):3740-8. doi: 10.1128/IAI.00142-09.
38. Ahmadzai H, Cameron B, Chui JJ, Lloyd A, Wakefield D, Thomas PS. Peripheral blood responses to specific antigens and CD28 in sarcoidosis. Respiratory Medicine (2012) 106(5):701-9.
39. Furusawa H, Suzuki Y, Miyazaki Y, Inase N, Eishi Y. Th1 and Th17 immune responses to viable Propionibacterium acnes in patients with sarcoidosis. Respiratory Investigation (2012) 50(3):104-9. doi: 10.1016/j.resinv.2012.07.001.
40. Tercelj M, Salobir B, Zupancic M, Wraber B, Rylander R. Inflammatory markers and pulmonary granuloma infiltration in sarcoidosis. Respirology (2013). doi: 10.1111/resp.12199.
41. Terčelj M, Salobir B, Harlander M, Rylander R. Fungal exposure in homes of patients with sarcoidosis-an environmental exposure study. Environmental Health (2011) 10(1).
42. Wahlstrom J, Dengjel J, Persson B, Duyar H, Rammensee HG, Stevanovic S, et al. Identification of HLA-DR-bound peptides presented by human bronchoalveolar lavage cells in sarcoidosis. The Journal of Clinical Investigation (2007) 117(11):3576-82. doi: 10.1172/JCI32401.
43. Wahlstrom J, Dengjel J, Winqvist O, Targoff I, Persson B, Duyar H, et al. Autoimmune T cell responses to antigenic peptides presented by bronchoalveolar lavage cell HLA-DR molecules in sarcoidosis. Clinical Immunology (2009) 133(3):353-63. doi: 10.1016/j.clim.2009.08.008.
44. Chen ES, Song Z, Willett MH, Heine S, Yung RC, Liu MC, et al. Serum amyloid A regulates granulomatous inflammation in sarcoidosis through Toll-like receptor-2. American Journal of Respiratory and Critical Care Medicine (2010) 181(4):360-71.
45. Bargagli E, Magi B, Olivieri C, Bianchi N, Landi C, Rottoli P. Analysis of serum amyloid A in sarcoidosis patients. Respiratory Medicine (2011) 105(5):775-80.
46. Zhang Y, Chen X, Hu Y, Du S, Shen L, He Y, et al. Preliminary characterizations of a serum biomarker for sarcoidosis by comparative proteomic approach with tandem-mass spectrometry in ethnic Han Chinese patients. Respiratory Research (2013) 14:18. doi: 10.1186/1465-9921-14-18.
47. Salazar A, Mana J, Fiol C, Hurtado I, Argimon JM, Pujol R, et al. Influence of serum amyloid A on the decrease of high density lipoprotein-cholesterol in active sarcoidosis. Atherosclerosis (2000) 152(2):497-502.
48. Dubaniewicz A. Microbial and human heat shock proteins as 'danger signals' in sarcoidosis. Human Immunology (2013) 74(12):1550-8. doi: 10.1016/j.humimm.2013.08.275.
49. Spagnolo P, Grunewald J. Recent advances in the genetics of sarcoidosis. Journal of Medical Genetics (2013) 50(5):290-7.
50. Grunewald J, Brynedal B, Darlington P, Nisell M, Cederlund K, Hillert J, et al. Different HLA-DRB1 allele distributions in distinct clinical subgroups of sarcoidosis patients. Respiratory Research (2010) 11:25. doi: 10.1186/1465-9921-11-25.
51. Sato H, Woodhead FA, Ahmad T, Grutters JC, Spagnolo P, van den Bosch JM, et al. Sarcoidosis HLA class II genotyping distinguishes differences of clinical phenotype across ethnic groups. Human Molecular Genetics (2010) 19(20):4100-11. doi: 10.1093/hmg/ddq325.
52. Wijnen PA, Nelemans PJ, Verschakelen JA, Bekers O, Voorter CE, Drent M. The role of tumor necrosis factor alpha G-308A polymorphisms in the course of pulmonary sarcoidosis. Tissue Antigens (2010) 75(3):262-8. doi: 10.1111/j.1399-0039.2009.01437.x.
53. Grubic Z, Peros-Golubicic T, Stingl K, Zunec R. The investigation of HLA microsatellites influence in predisposition to sarcoidosis among Croatians. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases: Official Journal of WASOG / World Association of Sarcoido (2011) 28(1):18-26.
54. Wennerstrom A, Pietinalho A, Vauhkonen H, Lahtela L, Palikhe A, Hedman J, et al. HLA-DRB1 allele frequencies and C4 copy number variation in Finnish sarcoidosis patients and associations with disease prognosis. Human Immunology (2012) 73(1):93-100. doi: 10.1016/j.humimm.2011.10.016.
55. Zhou Y, Shen L, Zhang Y, Jiang D, Li H. Human leukocyte antigen-A, -B, and -DRB1 alleles and sarcoidosis in Chinese Han subjects. Human Immunology (2011) 72(7):571-5. doi: 10.1016/j.humimm.2011.03.020.
56. Spagnolo P, Sato H, Grutters JC, Renzoni EA, Marshall SE, Ruven HJ, et al. Analysis of BTNL2 genetic polymorphisms in British and Dutch patients with sarcoidosis. Tissue Antigens (2007) 70(3):219- doi: 10.1111/j.1399-0039.2007.00879.x.
57. Morais A, Lima B, Peixoto MJ, Alves H, Marques A, Delgado L. BTNL2 gene polymorphism associations with susceptibility and phenotype expression in sarcoidosis. Respiratory Medicine (2012) 106(12):1771-7. doi: 10.1016/j.rmed.2012.08.009.
58. Milman N, Svendsen CB, Nielsen FC, van Overeem Hansen T. The BTNL2 A allele variant is frequent in Danish patients with sarcoidosis. The Clinical Respiratory Journal (2011) 5(2):105-11. doi: 10.1111/j.1752-699X.2010.00206.x.
59. Wijnen PA, Voorter CE, Nelemans PJ, Verschakelen JA, Bekers O, Drent M. Butyrophilin-like 2 in pulmonary sarcoidosis: a factor for susceptibility and progression? Human Immunology (2011) 72(4):342-7. doi: 10.1016/j.humimm.2011.01.011.
60. Suzuki H, Ota M, Meguro A, Katsuyama Y, Kawagoe T, Ishihara M, et al. Genetic characterization and susceptibility for sarcoidosis in Japanese patients: risk factors of BTNL2 gene polymorphisms and HLA class II alleles. Investigative Ophthalmolology & Visual Science (2012) 53(11):7109-15. doi: 10.1167/iovs.12-10491.
61. Veltkamp M, Wijnen PA, van Moorsel CH, Rijkers GT, Ruven HJ, Heron M, et al. Linkage between Toll-like receptor (TLR) 2 promotor and intron polymorphisms: functional effects and relevance to sarcoidosis. Clinical & Experimental Immunology (2007) 149(3):453-62. doi: 10.1111/j.1365-2249.2007.03428.x.
62. Daniil Z, Mollaki V, Malli F, Koutsokera A, Antoniou K, Rodopoulou P, et al. Polymorphisms and haplotypes in MyD88 are associated with the development of sarcoidosis: a candidate-gene association study. Molecular Biology Reports (2013) 40(7):4281-6.
63. Kim HS, Choi D, Lim LL, Allada G, Smith JR, Austin CR, et al. Association of interleukin 23 receptor gene with sarcoidosis. Disease Markers (2011) 31(1):17-24. doi: 10.3233/DMA-2011-0796.
64. Song GG, Kim J-H, Lee YH. Associations between TNF-α- 308 A/G and lymphotoxin-α+ 252 A/G polymorphisms and susceptibility to sarcoidosis: a meta-analysis. Molecular Biology Reports (2014) 41(1):259-67.
65. Hofmann S, Fischer A, Nothnagel M, Jacobs G, Schmid B, Wittig M, et al. Genome-wide association analysis reveals 12q13. 3-q14. 1 as new risk locus for sarcoidosis. European Respiratory Journal (2013) 41(4):888-900.
66. Vasakova M, Sterclova M, Kolesar L, Slavcev A, Skibova J, Striz I. Cytokine gene polymorphisms in sarcoidosis. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases: Official Journal of WASOG / World Association of Sarcoido (2010) 27(1):70-5.
67. Wijnen PA, Cremers JP, Nelemans PJ, Erckens RJ, Hoitsma E, Jansen TL, et al. Association of the TNF-α G-308A polymorphism with TNF-inhibitor response in sarcoidosis. European Respiratory Journal (2014):erj01694-2013.
68. Ten Berge B, Paats MS, Bergen IM, van den Blink B, Hoogsteden HC, Lambrecht BN, et al. Increased IL-17A expression in granulomas and in circulating memory T cells in sarcoidosis. Rheumatology (Oxford) (2012) 51(1):37-46. doi: 10.1093/rheumatology/ker316.
69. Miyara M, Amoura Z, Parizot C, Badoual C, Dorgham K, Trad S, et al. The immune paradox of sarcoidosis and regulatory T cells. The Journal of Experimental Medicine (2006) 203(2):359-70. doi: 10.1084/jem.20050648.
70. Co DO, Hogan LH, Il-Kim S, Sandor M. T cell contributions to the different phases of granuloma formation. Immunology Letters (2004) 92(1):135-42.
71. Chen ES, Moller DR. Sarcoidosis-scientific progress and clinical challenges. Nature Reviews Rheumatology (2011) 7(8):457-67.
72. Prasse A, Georges C, Biller H, Hamm H, Matthys H, Luttmann W, et al. Th1 cytokine pattern in sarcoidosis is expressed by bronchoalveolar CD4+ and CD8+ T cells. Clinical & Experimental Immunology (2000) 122(2):241-8.
73. Robinson B, McLemore TL, Crystal RG. Gamma interferon is spontaneously released by alveolar macrophages and lung T lymphocytes in patients with pulmonary sarcoidosis. Journal of Clinical Investigation (1985) 75(5):1488-95.
74. Moseley PL, Hemken C, Monick M, Nugent K, Hunninghake G. Interferon and growth factor activity for human lung fibroblasts. Release from bronchoalveolar cells from patients with active sarcoidosis. CHEST Journal (1986) 89(5):657-62.
75. Shigehara K, Shijubo N, Ohmichi M, Takahashi R, Kon S, Okamura H, et al. IL-12 and IL-18 are increased and stimulate IFN-gamma production in sarcoid lungs. The Journal of Immunology (2001) 166(1):642-9.
76. Stoll S, Jonuleit H, Schmitt E, Müller G, Yamauchi H, Kurimoto M, et al. Production of functional IL-18 by different subtypes of murine and human dendritic cells (DC): DC-derived IL-18 enhances IL-12-dependent Th1 development. European Journal of Immunology (1998) 28(10):3231-9.
77. Yoshimoto T, Takeda K, Tanaka T, Ohkusu K, Kashiwamura S-i, Okamura H, et al. IL-12 up regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-γ production. The Journal of Immunology (1998) 161(7):3400-7.
78. Facco M, Cabrelle A, Teramo A, Olivieri V, Gnoato M, Teolato S, et al. Sarcoidosis is a Th1/Th17 multisystem disorder. Thorax (2011) 66(2):144-50. doi: 10.1136/thx.2010.140319.
79. Richmond BW, Ploetze K, Isom J, Chambers-Harris I, Braun NA, Taylor T, et al. Sarcoidosis Th17 cells are ESAT-6 antigen specific but demonstrate reduced IFN-gamma expression. Journal of Clinical Immunology (2013) 33(2):446-55. doi: 10.1007/s10875-012-9817-6.
80. Bedoya SK, Lam B, Lau K, Larkin J, 3rd. Th17 cells in immunity and autoimmunity. Clinical and Developmental Immunology (2013) 2013:986789. doi: 10.1155/2013/986789.
81. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nature Immunology (2007) 8(9):942-9. doi: 10.1038/ni1496.
82. Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, Mattson JD, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nature Immunology (2007) 8(9):950-7. doi: 10.1038/ni1497.
83. Manel N, Unutmaz D, Littman DR. The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nature Immunology (2008) 9(6):641-9. doi: 10.1038/ni.1610.
84. Volpe E, Servant N, Zollinger R, Bogiatzi SI, Hupe P, Barillot E, et al. A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nature Immunology (2008) 9(6):650-7. doi: 10.1038/ni.1613.
85. Zissel G, Homolka J, Schlaak J, Schlaak M, Müller-Quernheim J. Anti-inflammatory cytokine release by alveolar macrophages in pulmonary sarcoidosis. American Journal of Respiratory and Critical Care Medicine (1996) 154(3):713-9.
86. Idali F, Wiken M, Wahlström J, Mellstedt H, Eklund A, Rabbani H, et al. Reduced Th1 response in the lungs of HLA-DRB1* 0301 patients with pulmonary sarcoidosis. European Respiratory Journal (2006) 27(3):451-9.
87. Urbankowski T, Hoser G, Domagala-Kulawik J. Th1/Th2/Th17related cytokines in the bronchoalveolar lavage fluid of patients with sarcoidosis: association with smoking. Polskie Archiwum Medycyny Wewnetrznej (2012) 122(7-8):320-5.
88. Judson MA, Marchell RM, Mascelli M, Piantone A, Barnathan ES, Petty KJ, et al. Molecular profiling and gene expression analysis in cutaneous sarcoidosis: the role of interleukin-12, interleukin-23, and the T-helper 17 pathway. Journal of the American Academy of Dermatology (2012) 66(6):901-10. doi: 10.1016/j.jaad.2011.06.017.
89. Patterson KC, Hogarth K, Husain AN, Sperling AI, Niewold TB. The clinical and immunologic features of pulmonary fibrosis in sarcoidosis. Translational Research (2012) 160(5):321-31.
90. Oswald-Richter KA, Richmond BW, Braun NA, Isom J, Abraham S, Taylor TR, et al. Reversal of global CD4+ subset dysfunction is associated with spontaneous clinical resolution of pulmonary sarcoidosis. The Journal of Immunology (2013) 190(11):5446-53. doi: 10.4049/jimmunol.1202891.
91. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. New England Journal of Medicine (2007) 357(21):2153-65. doi: doi:10.1056/NEJMra071714.
92. Patterson KC, Franek BS, Muller-Quernheim J, Sperling AI, Sweiss NJ, Niewold TB. Circulating cytokines in sarcoidosis: phenotype-specific alterations for fibrotic and non-fibrotic pulmonary disease. Cytokine (2013) 61(3):906-11. doi: 10.1016/j.cyto.2012.12.016.
93. Prokop S, Heppner FL, Goebel HH, Stenzel W. M2 polarized macrophages and giant cells contribute to myofibrosis in neuromuscular sarcoidosis. The American Journal of Pathology (2011) 178(3):1279-86.
94. Prasse A, Pechkovsky DV, Toews GB, Jungraithmayr W, Kollert F, Goldmann T, et al. A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. American Journal of Respiratory and Critical Care Medicine (2006) 173(7):781-92.
95. Wikén M, Idali F, Al Hayja MA, Grunewald J, Eklund A, Wahlström J. No evidence of altered alveolar macrophage polarization, but reduced expression of TLR2, in bronchoalveolar lavage cells in sarcoidosis. Respiratory Research (2010) 11(1):121-33.
96. Crespo J, Sun H, Welling TH, Tian Z, Zou W. T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Current Opinion in Immunology (2013) 25(2):214-21.
97. Mathew S, Bauer KL, Fischoeder A, Bhardwaj N, Oliver SJ. The anergic state in sarcoidosis is associated with diminished dendritic cell function. The Journal of Immunology (2008) 181(1):746-55.
98. Miyara M, Amoura Z, Parizot C, Badoual C, Dorgham K, Trad S, et al. The immune paradox of sarcoidosis and regulatory T cells. The Journal of Experimental Medicine (2006) 203(2):359-70.
99. Taflin C, Miyara M, Nochy D, Valeyre D, Naccache JM, Altare F, et al. FoxP3+ regulatory T cells suppress early stages of granuloma formation but have little impact on sarcoidosis lesions. The American Journal of Pathology (2009) 174(2):497-508. doi: 10.2353/ajpath.2009.080580.
100. Rappl G, Pabst S, Riemann D, Schmidt A, Wickenhauser C, Schutte W, et al. Regulatory T cells with reduced repressor capacities are extensively amplified in pulmonary sarcoid lesions and sustain granuloma formation. Clinical Immunology (2011) 140(1):71-83. doi: 10.1016/j.clim.2011.03.015.
101. Oswald-Richter KA, Richmond BW, Braun NA, Isom J, Abraham S, Taylor TR, et al. Reversal of global CD4+ subset dysfunction is associated with spontaneous clinical resolution of pulmonary sarcoidosis. The Journal of Immunology (2013) 190(11):5446-53.
102. Ahmadzai H, Cameron B, Chui JJ, Lloyd A, Wakefield D, Thomas PS. Peripheral blood responses to specific antigens and CD28 in sarcoidosis. Respiratory Medicine (2012) 106(5):701-9. doi: 10.1016/j.rmed.2012.01.012.
103. Vignali DA, Kuchroo VK. IL-12 family cytokines: immunological playmakers. Nature Immunology (2012) 13(8):722-8. doi: 10.1038/ni.2366.
104. Hata M, Sugisaki K, Miyazaki E, Kumamoto T, Tsuda T. Circulating IL-12 p40 is increased in the patients with sarcoidosis, correlation with clinical markers. Internal Medicine (2007) 46(17):1387-93.
105. Shigehara K, Shijubo N, Ohmichi M, Kamiguchi K, Takahashi R, Morita-Ichimura S, et al. Increased circulating interleukin-12 (IL-12) p40 in pulmonary sarcoidosis. Clinical & Experimental Immunology (2003) 132(1):152-7.
106. Rogge L, Papi A, Presky DH, Biffi M, Minetti LJ, Miotto D, et al. Antibodies to the IL-12 receptor beta 2 chain mark human Th1 but not Th2 cells in vitro and in vivo. Journal of immunology (1999) 162(7):3926-32.
107. Terasaki F, Ukimura A, Tsukada B, Fujita S, Katashima T, Otsuka K, et al. Enhanced expression of type 1 helper T-cell cytokines in the myocardium of active cardiac sarcoidosis. Circulation Journal: Official Journal of the Japanese Circulation Society (2008) 72(8):1303-7.
108. Bergeron A, Bonay M, Kambouchner M, Lecossier D, Riquet M, Soler P, et al. Cytokine patterns in tuberculous and sarcoid granulomas: correlations with histopathologic features of the granulomatous response. Journal of immunology (1997) 159(6):3034-43.
109. Moller DR, Forman JD, Liu MC, Noble PW, Greenlee BM, Vyas P, et al. Enhanced expression of IL-12 associated with Th1 cytokine profiles in active pulmonary sarcoidosis. Journal of immunology (1996) 156(12):4952-60.
110. Barbarin V, Petrek M, Kolek V, Van Snick J, Huaux F, Lison D. Characterization of p40 and IL-10 in the BALF of patients with pulmonary sarcoidosis. Journal of interferon & cytokine research: the official journal of the International Society for Interferon and Cytokine Research (2003) 23(8):449-56. doi: 10.1089/107999003322277865.
111. Kim DS, Jeon YG, Shim TS, Lim CM, Lee SD, Koh Y, et al. The value of interleukin-12 as an activity marker of pulmonary sarcoidosis. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases: Official Journal of WASOG / World Association of Sarcoido (2000) 17(3):271-6.
112. Meloni F, Caporali R, Marone Bianco A, Paschetto E, Morosini M, Fietta AM, et al. BAL cytokine profile in different interstitial lung diseases: a focus on systemic sclerosis. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases: Official Journal of WASOG / World Association of Sarcoido (2004) 21(2):111-8.
113. Antoniou KM, Tzouvelekis A, Alexandrakis MG, Tsiligianni I, Tzanakis N, Sfiridaki K, et al. Upregulation of Th1 cytokine profile (IL-12, IL-18) in bronchoalveolar lavage fluid in patients with pulmonary sarcoidosis. Journal of interferon & cytokine research: the official journal of the International Society for Interferon and Cytokine Research (2006) 26(6):400-5. doi: 10.1089/jir.2006.26.400.
114. Minshall EM, Tsicopoulos A, Yasruel Z, Wallaert B, Akoum H, Vorng H, et al. Cytokine mRNA gene expression in active and nonactive pulmonary sarcoidosis. The European respiratory journal (1997) 10(9):2034-9.
115. Taha RA, Minshall EM, Olivenstein R, Ihaku D, Wallaert B, Tsicopoulos A, et al. Increased expression of IL-12 receptor mRNA in active pulmonary tuberculosis and sarcoidosis. Am J Respir Crit Care Med (1999) 160(4):1119-23. doi: 10.1164/ajrccm.160.4.9807120.
116. Rastogi R, Du W, Ju D, Pirockinaite G, Liu Y, Nunez G, et al. Dysregulation of p38 and MKP-1 in response to NOD1/TLR4 stimulation in sarcoid bronchoalveolar cells. American Journal of Respiratory and Critical Care Medicine (2011) 183(4):500-10. doi: 10.1164/rccm.201005-0792OC.
117. Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, Mazzinghi B, et al. Phenotypic and functional features of human Th17 cells. The Journal of experimental medicine (2007) 204(8):1849-61.
118. Boniface K, Blumenschein WM, Brovont-Porth K, McGeachy MJ, Basham B, Desai B, et al. Human Th17 cells comprise heterogeneous subsets including IFN-γ-producing cells with distinct properties from the Th1 lineage. The Journal of Immunology (2010) 185(1):679-87.
119. Cooper AM, Magram J, Ferrante J, Orme IM. Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with Mycobacterium tuberculosis. The Journal of experimental medicine (1997) 186(1):39-45.
120. Fischer A, Nothnagel M, Franke A, Jacobs G, Saadati HR, Gaede KI, et al. Association of inflammatory bowel disease risk loci with sarcoidosis, and its acute and chronic subphenotypes. European Respiratory Journal (2011) 37(3):610-6. doi: 10.1183/09031936.00049410.
121. Veltkamp M, Van Moorsel CH, Rijkers GT, Ruven HJ, Van Den Bosch JM, Grutters JC. Toll-like receptor (TLR)-9 genetics and function in sarcoidosis. Clinical & Experimental Immunology (2010) 162(1):68-74. doi: 10.1111/j.1365-2249.2010.04205.x.
122. Pflanz S, Timans JC, Cheung J, Rosales R, Kanzler H, Gilbert J, et al. IL-27, a Heterodimeric Cytokine Composed of EBI3 and p28 Protein, Induces Proliferation of Naive CD4+ T Cells. Immunity (2002) 16(6):779-90.
123. Owaki T, Asakawa M, Morishima N, Hata K, Fukai F, Matsui M, et al. A role for IL-27 in early regulation of Th1 differentiation. The Journal of Immunology (2005) 175(4):2191-200.
124. Owaki T, Asakawa M, Fukai F, Mizuguchi J, Yoshimoto T. IL-27 induces Th1 differentiation via p38 MAPK/T-bet-and intercellular adhesion molecule-1/LFA-1/ERK1/2-dependent pathways. The Journal of Immunology (2006) 177(11):7579-87.
125. Kalliolias GD, Ivashkiv LB. IL-27 activates human monocytes via STAT1 and suppresses IL-10 production but the inflammatory functions of IL-27 are abrogated by TLRs and p38. The Journal of Immunology (2008) 180(9):6325-33.
126. Villarino A, Hibbert L, Lieberman L, Wilson E, Mak T, Yoshida H, et al. The IL-27R (WSX-1) is required to suppress T cell hyperactivity during infection. Immunity (2003) 19(5):645-55.
127. Stumhofer JS, Silver JS, Laurence A, Porrett PM, Harris TH, Turka LA, et al. Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nature Immunology (2007) 8(12):1363-71.
128. Sweeney CM, Lonergan R, Basdeo SA, Kinsella K, Dungan LS, Higgins SC, et al. IL-27 mediates the response to IFN-beta therapy in multiple sclerosis patients by inhibiting Th17 cells. Brain, Behavior and Immunity (2011) 25(6):1170-81. doi: 10.1016/j.bbi.2011.03.007.
129. Fitzgerald DC, Fonseca-Kelly Z, Cullimore ML, Safabakhsh P, Saris CJ, Zhang G-X, et al. Independent and interdependent immunoregulatory effects of IL-27, IFN-β, and IL-10 in the suppression of human Th17 cells and murine experimental autoimmune encephalomyelitis. The Journal of Immunology (2013) 190(7):3225-34.
130. Apetoh L, Quintana FJ, Pot C, Joller N, Xiao S, Kumar D, et al. The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nature Immunology (2010) 11(9):854-61.
131. Kalliolias GD, Ivashkiv LB. IL-27 activates human monocytes via STAT1 and suppresses IL-10 production but the inflammatory functions of IL-27 are abrogated by TLRs and p38. The Journal of Immunology (2008) 180(9):6325-33.
132. Judson MA, Marchell RM, Mascelli M, Piantone A, Barnathan ES, Petty KJ, et al. Molecular profiling and gene expression analysis in cutaneous sarcoidosis: the role of interleukin-12, interleukin-23, and the T-helper 17 pathway. Journal of the American Academy of Dermatology (2012) 66(6):901-10.
133. Pearl JE, Khader SA, Solache A, Gilmartin L, Ghilardi N, Cooper AM. IL-27 signaling compromises control of bacterial growth in mycobacteria-infected mice. The Journal of Immunology (2004) 173(12):7490-6.
134. Morandi F, Di Carlo E, Ferrone S, Petretto A, Pistoia V, Airoldi I. IL-27 in Human Secondary Lymphoid Organs Attracts Myeloid Dendritic Cells and Impairs HLA Class I-Restricted Antigen Presentation. Journal of immunology (2014). doi: 10.4049/jimmunol.1302656.
135. Zeitvogel J, Werfel T, Wittmann M. IL-27 acts as a priming signal for IL-23 but not IL-12 production on human antigen-presenting cells. Experimental Dermatology (2012) 21(6):426-30. doi: 10.1111/j.1600-0625.2012.01484.x.
136. Li J, Zhao Q, Xing W, Feng J, Wu H, Li H, et al. Interleukin-27 enhances the production of tumour necrosis factor-alpha and interferon-gamma by bone marrow T lymphocytes in aplastic anaemia. British Journal of Haematology (2011) 153(6):764-72. doi: 10.1111/j.1365-2141.2010.08431.x.
137. Li X, Mai J, Virtue A, Yin Y, Gong R, Sha X, et al. IL-35 is a novel responsive anti-inflammatory cytokine-a new system of categorizing anti-inflammatory cytokines. PLoS One (2012) 7(3):e33628.
138. Guttek K, Reinhold D. Stimulated human peripheral T cells produce high amounts of IL-35 protein in a proliferation-dependent manner. Cytokine (2013) 64(1):46-50.
139. Seyerl M, Kirchberger S, Majdic O, Seipelt J, Jindra C, Schrauf C, et al. Human rhinoviruses induce IL-35-producing Treg via induction of B7-H1 (CD274) and sialoadhesin (CD169) on DC. European Journal of Immunology (2010) 40(2):321-9. doi: 10.1002/eji.200939527.
140. Niedbala W, Wei XQ, Cai B, Hueber AJ, Leung BP, McInnes IB, et al. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. European Journal of Immunology (2007) 37(11):3021-9. doi: 10.1002/eji.200737810.
141. Collison LW, Delgoffe GM, Guy CS, Vignali KM, Chaturvedi V, Fairweather D, et al. The composition and signaling of the IL-35 receptor are unconventional. Nature Immunology (2012) 13(3):290-9. doi: 10.1038/ni.2227.
142. Olson BM, Sullivan JA, Burlingham WJ. Interleukin 35: A Key Mediator of Suppression and the Propagation of Infectious Tolerance. Frontiers in Immunology (2013) 4:315. doi: 10.3389/fimmu.2013.00315.
143. Ye S, Wu J, Zhou L, Lv Z, Xie H, Zheng S. Interleukin-35: the future of hyperimmune-related diseases? Journal of Interferon & Cytokine Research: The Official Journal of the International Society for Interferon and Cytokine Resea (2013) 33(6):285-91. doi: 10.1089/jir.2012.0086.
144. Collison LW, Chaturvedi V, Henderson AL, Giacomin PR, Guy C, Bankoti J, et al. IL-35-mediated induction of a potent regulatory T cell population. Nature Immunology (2010) 11(12):1093-101. doi: 10.1038/ni.1952.
145. Wang RX, Yu CR, Dambuza IM, Mahdi RM, Dolinska MB, Sergeev YV, et al. Interleukin-35 induces regulatory B cells that suppress autoimmune disease. Nat Med (2014) 20(6):633-41. doi: 10.1038/nm.3554.
146. Bai J, Qiu SL, Zhong XN, Huang QP, He ZY, Zhang JQ, et al. Erythromycin enhances CD4+Foxp3+ regulatory T-cell responses in a rat model of smoke-induced lung inflammation. Mediators of inflammation (2012) 2012:410232. doi: 10.1155/2012/410232.
147. Whitehead GS, Wilson RH, Nakano K, Burch LH, Nakano H, Cook DN. IL-35 production by inducible costimulator (ICOS)-positive regulatory T cells reverses established IL-17-dependent allergic airways disease. The Journal of allergy and clinical immunology (2012) 129(1):207-15 e1-5. doi: 10.1016/j.jaci.2011.08.009.
148. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature (2007) 450(7169):566-9. doi: 10.1038/nature06306.
149. Judson MA, Baughman RP, Costabel U, Drent M, Gibson KF, Raghu G, et al. Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. European Respiratory Journal (2014):erj00009-2014.
150. Hommes DW, Mikhajlova TL, Stoinov S, Štimac D, Vucelic B, Lonovics J, et al. Fontolizumab, a humanised anti-interferon γ antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut (2006) 55(8):1131-7.